Treatment Pathway and Clinical Outcomes of the Population with Muscle-invasive Bladder Cancer in Italy: A Real-world Analysis with Administrative Databases

From this real-world analysis, Italian patients with MIBC emerged as a population of elderly subjects (> 75 years) burdened by comorbidities. Treatment choice was influenced by other factors rather than cisplatin eligibility since only 11% of patients with CrCl ≥ 60 ml/min in 2018 and 20% in 2022 were treated before cystectomy, highlighting a scenario of low adherence to guidelines with underutilization of neoadjuvant chemotherapy.